ONCOBAX®-AK, a game-changer Live Biotherapeutic Product for anticancer immunotherapy

Time: 5:30 pm
day: Day One – Track B – 3


  • The composition of the gut microbiota influences the effectiveness of anticancer immunotherapy
  • EverImmune has developed Oncobax®-AK, a breakthrough microbiome technology as oral adjuvant for anticancer immunotherapy in
  • NSCLC and RCC patients treated with ICIs, that will enter into clinics 2nd quarter 2022.
  • EverImmune has developed companion diagnosis tools to identify patients amenable to Oncobax®-AK